Radiopharm Theranostics announced the approval of αVβ6 Integrin for the Phase 1 trial

Radiopharm Theranostics Limited (ASX: RAD) announced that it had received US Food and Drug Administration (FDA) Investigational New Drug Application (IND) approval for its αVβ6 Integrin (RAD301) technology. This approval allows the company to commence its phase 1 trial in ambulatory patients with pancreatic cancer. The company aims to begin at the end of the first quarter of CY23 with an estimated close by the third quarter of CY23.

The company is doing clinical site preparation for the trial, expecting to close the first subject at Montefiore Einstein Cancer Centre in New York. Early-phase clinical trials are a high priority to address the needs of its diverse Bronx community as well as patients with cancer around the nation and the world.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com